Omeros Corporation Initiates Sales of OMIDRIA® in Europe

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced initial sales of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% in Europe. OMIDRIA, approved and commercially available in the U.S., is also approved in the European Union (EU) for use in cataract and lens replacement surgery to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. These sales satisfy the “sunset clause” provision in the EU a

Full Story →